# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The provisional result amount to a net gain of CHF 9.8 million for the six-month period ended June 30, 2024 compared to a net l...
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Addex Therapeutics (NASDAQ:ADXN) with a Buy and maintains $30 ...
Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatmen...
TRIB: 105% | Trinity Biotech shares are trading higher after the company announced an increase in projected revenue for its Tri...
Under the terms of the agreement, Addex is eligible for payment of up to USD 330 million on successful achievement of prespecif...